Annovis Bio Inc. (ANVS): Price and Financial Metrics

Annovis Bio Inc. (ANVS): $12.07

0.73 (+6.44%)

POWR Rating

Component Grades













ANVS Stock Price Chart Interactive Chart >

Price chart for ANVS

ANVS Price/Volume Stats

Current price $12.07 52-week high $132.00
Prev. close $11.34 52-week low $8.39
Day low $11.36 Volume 50,400
Day high $12.20 Avg. volume 56,232
50-day MA $10.44 Dividend yield N/A
200-day MA $18.01 Market Cap 98.54M

Annovis Bio Inc. (ANVS) Company Bio

Annovis Bio, Inc. develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders. It offers posiphen compound for mild cognitive impairment and early stage Alzheimer's disease and bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.

ANVS Latest News Stream

Event/Time News Detail
Loading, please wait...

ANVS Latest Social Stream

Loading social stream, please wait...

View Full ANVS Social Stream

Latest ANVS News From Around the Web

Below are the latest news stories about Annovis Bio Inc that investors may wish to consider to help them evaluate ANVS as an investment opportunity.

Lab Notes: AmerisourceBergen teams with UK tech firm; Chimeron Bio relocates to Center City

News out of Greater Philadelphia's life sciences industry this week includes a pharmaceutical packaging partnership, a cell and gene therapy distribution alliance, a lease deal, a gene therapy candidate, and more. Here's the roundup: West Pharmaceutical Services The Exton-based designer and manufacturer of injectable pharmaceutical packaging and delivery systems entered into an exclusive supply and technology agreement with specialty glass and materials maker Corning Inc. According to the companies, the deal will facilitate a multimillion-dollar capital and research and development investment to expand work on Corning's Valor glass technology and to produce advanced injectable drug packaging and delivery systems for the pharmaceutical industry.

Yahoo | January 28, 2022

FDA Guides Annovis Bio For Two Phase 3 Buntanetap Trial In Parkinson's Disease

Annovis Bio Inc (NYSE: ANVS) has completed a Type B meeting with the FDA regarding its planned Phase 3 studies of Buntanetap for the treatment of Parkinson's Disease (PD) as an offshoot of the Company's clinical program in Alzheimer's Disease (AD). Following the Company's submission of Phase 2 data and the chronic toxicology data in animals, the Company requested directions to further develop Buntanetap in PD. The FDA guided initiating the Phase 3 clinical studies of Buntanetap for PD parallel w

Yahoo | January 25, 2022

Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease

FDA gives guidance for two Phase 3 clinical trials of Buntanetap in Parkinson's Disease Berwyn, Pennsylvania--(Newsfile Corp. - January 25, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the company held a successful Type B meeting with the U.S. Food and Drug Administration (FDA) with regard to the Company's planned Phase 3 clinical studies of Buntanetap for the treatment of P

Yahoo | January 25, 2022

As Annovis Bio, Inc.'s market cap (NYSE:ANVS) drops to US$117m, insiders might be questioning their decision to buy earlier this year

The recent price decline of 18% in Annovis Bio, Inc.'s ( NYSE:ANVS ) stock may have disappointed insiders who bought...

Yahoo | January 19, 2022

Annovis Bio Enhances Leadership Team with Two Senior Appointments

Company Appoints Eve Damiano, MS, RAC, as Senior Vice President of Regulatory OperationsCompany Promotes Cheng Fang, Ph.D., to Senior Vice President of Research & DevelopmentBerwyn, Pennsylvania--(Newsfile Corp. - January 10, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the appointment of Eve Damiano, MS, RAC, as its new Senior Vice President of Regulatory Operations, and the pro

Yahoo | January 10, 2022

Read More 'ANVS' Stories Here

ANVS Price Returns

1-mo 22.66%
3-mo -12.73%
6-mo -38.98%
1-year -87.56%
3-year N/A
5-year N/A
YTD -31.34%
2021 133.16%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4698 seconds.